Celcuity's Gedatolisib Shows Superior Efficacy in Phase 3 Breast Cancer Trial
CELC has more than doubled off its 52-week low of $10.5 on elevated volume (2.1× avg).
Summary
Celcuity announced detailed positive Phase 3 trial results for gedatolisib in PIK3CA mutant breast cancer, showing superior efficacy and a favorable safety profile, reinforcing its potential as a new standard of care.
Key Events · Product Development and Regulatory · CELC
-
Superior Efficacy in PIK3CA Mutant Breast Cancer
The gedatolisib-triplet regimen doubled the likelihood of survival without disease progression or death (HR=0.50; p<0.0001) and achieved a median progression-free survival (PFS) of 11.1 months versus 5.6 months for the comparator (alpelisib plus fulvestrant).
-
New Milestones Achieved
The VIKTORIA-1 trial is the first Phase 3 study to demonstrate superiority of one PAM inhibitor over another. The gedatolisib-triplet also achieved the highest reported median PFS (11.1 months) and objective response rate (48.9%) in second-line HR+/HER2- advanced breast cancer.
-
Favorable Safety Profile
Both gedatolisib regimens were generally well tolerated with mostly low-grade treatment-related adverse events and lower discontinuation rates compared to the alpelisib plus fulvestrant group.
-
Upcoming sNDA Submission
Celcuity intends to submit these detailed data as a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and other regulatory authorities.
Analysis · CELC · Industrial Applications And Services
This filing provides detailed, highly positive efficacy and safety results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial for gedatolisib. The data demonstrates statistically significant and clinically meaningful superiority over a comparator drug, establishing new benchmarks for progression-free survival and objective response rates in this patient population. These results strengthen the drug's commercial potential and will support a supplemental New Drug Application (sNDA) submission, building on the existing FDA Priority Review for the wild-type cohort.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELC was trading at $91.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6B. The 52-week trading range was $10.50 to $151.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.